Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New NIH Center May Offer More Opportunity For FDA Collaboration

This article was originally published in The Gray Sheet

Executive Summary

FDA hopes the National Institute of Health’s proposed new National Center for Advancing Translational Science will trigger more collaboration between the two agencies through shared grant making, FDA Commissioner Margaret Hamburg said last week.

You may also be interested in...



FDA, NIH Devise Regulatory Research Agenda, Look For Financing

The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translational Science Awards program.

Regulatory Science Plan Would Create New Office In FDA

Commissioner Margaret Hamburg released details of FDA's regulatory science plan Oct. 6, and said she is "guardedly optimistic" legislators will come up with the money needed to grow the agency's regulatory science capacity

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

UsernamePublicRestriction

Register

MT030662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel